The Norwegian Immunotherapy in Multiple Myeloma Study

Summary

The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.

Conditions

• Myeloma Multiple
• Plasma Cell Leukemia
• AL Amyloidosis

Interventions

DRUG

Teclistamab

Real-world use and dosing

DRUG

Elranatamab

Real-world use and dosing

BIOLOGICAL

Ciltacabtagene Autoleucel

Real-world use.

DRUG

Talquetamab

Real-world use and dosing

BIOLOGICAL

Idecabtagene vicleucel

Real-world use and dosing

Sponsors & Collaborators

• Norwegian University of Science and Technology

  collaborator OTHER

• Haukeland University Hospital

  collaborator OTHER

• Helse Stavanger HF

  collaborator OTHER_GOV

• Oslo University Hospital

  collaborator OTHER

• University Hospital, Akershus

  collaborator OTHER

• Sykehuset i Vestfold Hospital Trust

  collaborator UNKNOWN

• University Hospital of North Norway

  collaborator OTHER

• Ålesund Hospital, Norway

  collaborator UNKNOWN

• Helse Nord-Trøndelag HF

  collaborator OTHER

• Sorlandet Hospital HF

  collaborator OTHER_GOV

• Førde Hospital Trust

  collaborator OTHER

• Molde Hospital

  collaborator OTHER

• Bodø Hospital, Norway

  collaborator UNKNOWN

• Helse Fonna

  collaborator OTHER

• Volda Hospital

  collaborator OTHER

• Diakonhjemmet Hospital

  collaborator OTHER

• Telemark Hospital Trust

  collaborator UNKNOWN

• Kristiansund Hospital

  collaborator OTHER

• Vestre Viken Hospital Trust

  collaborator OTHER

• Lovisenberg Diakonale Hospital

  collaborator OTHER

• Sykehuset Innlandet HF

  collaborator OTHER

• St. Olavs Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-01-15

Primary Completion

2029-01-31

Completion

2037-12-01

Countries

• Norway

Study Locations